Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158914 | 0.87 | TRPM4 (0.48) | TRPM4ALOX5TNKSTNKS2PTPN1 | |
| SCHEMBL22228567 | 0.85 | TRPM4 (0.47) | TRPM4ALOX5PTPN1MAOAMAOB | |
| SCHEMBL18049802 | 0.81 | NQO2 (0.41) | TRPM4ALOX5PTPN1MAOAMAOB | |
| SCHEMBL18049804 | 0.80 | TRPM4 (0.42) | TRPM4ALOX5PTPN1MAOAMAOB | |
| SCHEMBL16283926 | 0.79 | ALDH1A1 (0.46) | TNKSTNKS2PTPN1MAOANQO2 | |
| SCHEMBL17383050 | 0.79 | NQO2 (0.44) | ALOX5TNKSTNKS2PTPN1NQO2 | |
| SCHEMBL14951318 | 0.79 | PTPN1 (0.46) | ALOX5TNKSTNKS2PTPN1NQO2 | |
| SCHEMBL9950434 | 0.78 | MAPT (0.42) | ALOX5TNKSTNKS2PTPN1NQO2 | |
| SCHEMBL18049820 | 0.77 | CYP1A1 (0.43) | TRPM4ALOX5TNKSTNKS2NQO2 | |
| SCHEMBL19197073 | 0.76 | MEN1 (0.42) | ALOX5TNKSTNKS2PTPN1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | TRPM4 1074/4885ALOX5 156/4885TNKS 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.